Modality
Gene Editing
MOA
AuroraAi
Target
Aβ
Pathway
Sphingolipid
ACCMSAsthma
Development Pipeline
Preclinical
~Jul 2011
→ ~Oct 2012
Phase 1
~Jan 2013
→ ~Apr 2014
Phase 2
~Jul 2014
→ ~Oct 2015
Phase 3
~Jan 2016
→ ~Apr 2017
NDA/BLA
Jul 2017
→ Apr 2026
NDA/BLACurrent
NCT07047163
2,259 pts·Asthma
2017-07→2026-04·Terminated
2,259 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-04-183w awayPh3 Readout· Asthma
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2026-04-18 · 3w away
Asthma
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07047163 | NDA/BLA | Asthma | Terminated | 2259 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| ARG-314 | Argenx | Approved | Aβ |